Evidence map›Paper›PMID 42737652›Full record

ArticleInternational journal of molecular sciences2026

Genetic Code Expansion Enables Oriented, Site-Specific Conjugation of DARPins to Lipid Nanoparticles for Selective mRNA Delivery to CD8

Anastasiia Dakhnevich, Ildus Pateev, Ivan A Skvortsov, Sofia Yarmachkova, Daniil Shevyrev, Anastasia Chubarova, Mariia Gasina, Nadezhda Cherepanova, Elizaveta D Siaglova, Vasiliy Reshetnikov and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anastasiia DakhnevichBiotechnology Department, Sirius University of Science and Technology, 354349 Sirius, Russia.ORCID 0009-0008-6063-4079
Ildus PateevBiotechnology Department, Sirius University of Science and Technology, 354349 Sirius, Russia.ORCID 0000-0002-1992-6060
Ivan A SkvortsovBiotechnology Department, Sirius University of Science and Technology, 354349 Sirius, Russia.ORCID 0000-0002-8524-4754
Sofia YarmachkovaBiotechnology Department, Sirius University of Science and Technology, 354349 Sirius, Russia.
Daniil ShevyrevBiotechnology Department, Sirius University of Science and Technology, 354349 Sirius, Russia.ORCID 0000-0002-7084-081X
Anastasia ChubarovaBiotechnology Department, Sirius University of Science and Technology, 354349 Sirius, Russia.ORCID 0009-0002-4917-8988
Mariia GasinaBiotechnology Department, Sirius University of Science and Technology, 354349 Sirius, Russia.
Nadezhda CherepanovaMedicinal Chemistry Core Facility, Sirius University of Science and Technology, 354349 Sirius, Russia.
Elizaveta D SiaglovaBiomaterials Core Facility, Sirius University of Science and Technology, 354349 Sirius, Russia.
Vasiliy ReshetnikovBiotechnology Department, Sirius University of Science and Technology, 354349 Sirius, Russia.ORCID 0000-0002-2932-0804
Maksim V BaranovBiotechnology Department, Sirius University of Science and Technology, 354349 Sirius, Russia.
Roman A IvanovBiotechnology Department, Sirius University of Science and Technology, 354349 Sirius, Russia.ORCID 0000-0002-9573-4183

Funding

Scientific and technological development of the «Sirius» Federal Territory 18-03
6 · The paper itself

Abstract

Lipid nanoparticles (LNPs) are an effective platform for delivering therapeutic payloads, but their use for targeting specific cell populations in vivo is limited by a lack of specificity. To address this issue, we developed an innovative approach for creating targeted LNPs based on the post-insertion of protein-lipid conjugates. By expanding the genetic code, a single p-azido-L-phenylalanine residue was specifically incorporated into a DARPin against murine CD8, enabling copper-free click-chemistry with dibenzocyclooctyne (DBCO) to functionalize the particle surface with DARPin conjugates. DARPin-LNP characterization demonstrated preservation of particle size and acquisition of a characteristic negative charge after DARPin insertion, confirming successful post-insertion. In vitro experiments using primary murine splenic T-cells showed that targeted LNPs selectively transfected CD8

Indexed as

CD8-Positive T-LymphocytesGenetic CodeLipidsNanoparticlesRNA, MessengerAnimalsClick ChemistryLiposomesMicePhenylalanineLipid NanoparticlesLipidsLiposomesPhenylalanineRNA, MessengerCD8 T-cellscell-targeted gene therapyclick-chemistryDARPingenetic code expansionlipid nanoparticles (LNP)mRNA

Identifiers

PMID42737652
PMCPMC13565844

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.